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Furosemide or frusemide (FUR) is a loop diuretic widely used in
the treatment of congestive heart failure and edema1. As a
commercial product, this active pharmaceutical ingredient (API)
is administered basically as an oral tablet and an injectable
solution2. FUR is a potent diuretic with some associated side
effects. Additionally, FUR is included in the World Anti-Doping
Agency's banned drug list3. Therefore, we are always concerned
about the availability of a valid and simple analytical method for
FUR determination in pharmaceutical dosage forms.
According to the reviews published by Espinosa-Bosch et al.4,5,
a variety of analytical methods has been proposed for determining
FUR in drugs. Li et al.6 also mention various methods for
determining FUR since introducing it to the pharmaceutical
market. In the present decade, several methods including the
resonance Rayleigh scattering technique6, spectrophotometric7–9,
ﬂuorescence10,11, luminescence12 and liquid chromatography13–16
have been proposed to quantify FUR in pharmaceutical samples.
The ofﬁcial methods for the determination of FUR as a bulk
drug are based on titrimetry17–21 while the ofﬁcial methods for
FUR determination in tablets are based on a liquid chromato-
graphic method17 and an UV spectrophotometric method19,22.
However, until now, no direct Fourier transform infrared (FTIR)
spectroscopy has been recommended for the quantitative determi-
nation of FUR in solid dosage forms.
Because of its inherent simplicity and availability in most
pharmaceutical laboratories, FTIR is a technique which can be
used in quality control laboratories not only for qualitative, but
also for quantitative purposes. Since the wavenumber and the
respective intensity of an absorption maximum depend on a
particular group of the chemical structure of a substance, this
measurement can be used to quantitatively determine a substance.
Fig. 1 illustrates how rich the structure of FUR is in regards to
diverse groups which absorb in the mid-IR (MIR) region.
For the past two decades, the transmission FTIR spectroscopy
has undergone signiﬁcant application for quantitative purposes,
several in the pharmaceutical analysis ﬁeld23–33. As suggested
above, a FTIR spectrum can be used for verifying the identity and
purity of API and for detecting any spectral interference originat-
ing from the excipients. A conventional calibration curve approach
is used as a method for analyzing the FTIR absorption spectrum.
However, it usually requires chemometric methods in order to
improve the data quality whenever applicable. Derivative spectro-
scopy (DS) is one of the easiest pre-processing methods. It is a
useful technique for ﬁnding bands hidden in broad spectral
features. Virtually, all current FTIR spectrometers generate deri-
vative spectra by mathematical means. Consequently, an additional
instrument is not required. Specialized literature concerning DS
has been amply described34–36.S
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Figure 1 Chemical structure of 4-chloro-2-[(furan-2-ylmethyl)
amino]-5-sulfamoylbenzoic acid (FUR).Therefore, this study aims to develop a new method for the
qualitative and quantitative determination of FUR by FTIR-DS in
liquid cell-through transmission mode. The method uses the same
extraction procedure of compendium pharmacopoeias. This
approach represents a real alternative for not only identifying
incoming raw materials, but also analyzing them quantitatively,
and for assessing pharmaceutical quality of FUR tablets from
multinational markets without using separating techniques. By
comparison with compendial and non-compendial analytical
methods, the proposed FTIR-DS method reduces solvent con-
sumption and eliminates the use of reagents.2. Materials and methods
2.1. Equipment
A Perkin-Elmer Spectrum 2000 FTIR spectrophotometer (Nor-
walk, CT, USA) equipped with a temperature stabilized deuterated
triglycine sulfate detector, a KBr–Ge coated beam splitter, and a
globar IR source was employed for FTIR spectra acquisition.
A Wilmad Labglass FTIR liquid transmission cell (Buena, NJ, USA)
was used for sampling. Its circular conﬁguration was a general
purpose liquid transmission cell. It involved ZnSe windows
(32 mm diameter, 3 mm thick) and an appropriate PTFE spacer
of 0.05 mm optical path length. The sample was introduced by
ﬁlling ports using a 3 mL syringe.
2.2. Reagents and samples
FUR reference substance of 98.0% purity was purchased from
Sigma-Aldrich (St Louis, MO, USA) and 99.05% FUR raw
material purity was kindly supplied by Valmorca Lab (Mérida,
Venezuela). N,N-Dimethylformamide (DMF) of 99.9% purity was
purchased from Mallinckrodt (Paris, Kentucky, USA). Commer-
cial pharmaceutical 20 mg/Tab and 40 mg/Tab FUR tablets were
purchased from local market (Mérida, Venezuela) but were
manufactured by different laboratories: Sanoﬁ Aventis (Caracas,
Venezuela), Proula (Lagunillas, Venezuela), PluxAndex (El Vigía,
Venezuela), Meyer Daliol (Caracas, Venezuela) and Genéricos Rx
(Caracas, Venezuela).
2.3. Preparation of a standard solution
A 40.0 mg/mL FUR stock solution was prepared in DMF and a
20.0 mg/mL diluted FUR stock solution was also prepared in DMF
by diluting 1:1 (v/v). The stock solution was kept protected from
light using amber colored ﬂasks and refrigerated. After being
diluted with DMF, increasing volumes of FUR stock solutions
were quantitatively transferred to a set of 10 mL volumetric ﬂasks
to provide solutions within the 2.0–20.0 mg/mL concentration
range. Final standard solutions were kept protected from light.
2.4. Preparation of a sample solution
Twenty tablets were accurately weighed, ﬁnely pulverized, and
thoroughly mixed. An accurately weighed portion of pulverized
tablets equivalent to 100 mg of FUR was transferred to a 10-mL
volumetric ﬂask, 9 mL of diluting solvent (DMF) was added, and
was sonicated for 30 min. After cooling, the diluting solvent was
added to bring the volume to the mark. Finally, it was mixed,
Máximo Gallignani et al.378centrifuged at 2500 rpm for 5 min, and ﬁltered, discarding the ﬁrst
2.5 mL of the ﬁltrate. All sample solutions were ﬁltered through
0.22 μm analytical Nylon ﬁlters (New Jersey, USA). Samples for
the standard addition technique were obtained by increasing
volumes from 0 mL to 9 mL of the 20 mg/mL FUR stock solution
to a set of 10 mL volumetric ﬂasks containing 1.0 mL of sample
solution equivalent to 20 mg/mL FUR. They were then quantita-
tively diluted to obtain solutions within the nominal concentration
range.2.5. Method validation
Validation of the analytical method and procedures was con-
ducted, unless otherwise speciﬁed herein, following a tutorial from
LabCompliance, a private organization devoted to validation and
qualiﬁcation in analytical laboratories37.3. Results and discussion
3.1. Spectral characterization of FUR in DMF
FUR is insoluble in water or in chloroform. It is freely soluble in
acetone, DMF and alkali-metal hydroxide solutions. We selected
DMF taking into account FUR solubility, volatility and IR
transparency. This is considered a green chemical solvent due to
its amenable properties, such as low toxicity, low water miscibility
and low volatility38.
As can be expected, in order to use DMF as a solvent in the IR
spectroscopy, a reduced optical path length was required. An
optical path length of 0.05 mm resulted adequate for the purpose
of ﬁnding transparency zones in the MIR region. A guide to path
length selection and cell thickness, depending on analyte concen-
tration in the sample solution, has been described by Stuart39.
Using DMF as the background, transparency zones were found in
the IR ﬁngerprint range (~ν/cm1) as follows: 1370–1270, 1240–
1120 and 1050–500 (Fig. 2).
The FTIR spectrum of FUR obtained in the solid phase, KBr
pellets, shows well deﬁned bands with relatively high intensity in the
1800–400 cm1 wavenumber range. Using the KBr pellet, compar-
ison of the FUR analyte FTIR spectrum vs. the FUR reference
spectrum from the International Pharmacopoeia website21 showed an1400 1200 1000 800 600 450
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Figure 2 Liquid phase FTIR spectrum of DMF (spectrum line 1),
FUR standard 10 mg/mL (spectrum line 2), and FUR pharmaceutical
sample (spectrum line 3). The nominal concentration of the pharma-
ceutical product is equivalent to 10 mg/mL. Spectra are the average of
10 accumulated scans obtained with a nominal resolution of 4 cm1
using DMF as background correction.excellent frequency correlation. The chemical sulfur group (Fig. 1)
gives speciﬁcity to the FUR chemical structure. Indeed, SO2 and SO
sulfur compound groups produced strong IR bands in the 1400–
1000 cm1 range. The expected S¼O stretching bands for sulfo-
namides are as follows: 1390–1290 cm1 range for SO2 asymmetric
stretching; 1190–1120 cm1 range for SO2 symmetric stretching;
and 1060–1020 cm1 range for S¼O stretching39.
Therefore, taking into account the above information, the FUR
FTIR spectrum, using DMF as background, showed two notable
spectral bands in the MIR with maximum wavenumbers located at
1335 cm1 and 1165 cm1 (Fig. 2). The spectra also showed that
the presence of excipients, at the stated concentrations in the
formulation, did not have any additional IR bands interfering with
the mentioned IR absorption bands belonging to FUR.
3.2. Selection of the analytical spectral band
The two FUR spectral bands in the MIR, referred to above,
showed a slightly spectral baseline shift for FUR in the pharma-
ceutical formulation. Under these circumstances, we decided to use
a pre-processing method. When analyzing spectral data, our
research group commonly used the concept of derivatizing spectral
data, one of the most used pre-processing methods in spectro-
scopy. It allows for minimizing unwanted variations such as
baseline shift, enhancement of spectral signiﬁcant differences,
and eliminating interferences by broad band constituents34,35.
The DS revealed that ﬁrst-order spectrum, a plot of dA/dλ vs
1/λ, allowed eliminating baseline shifts. However, apparently the
FUR standard spectrum did not highly resemble the FUR sample
(ﬁgure not shown). Additional spectroscopic processing, using the
second-order spectrum, d2A/d(1/λ)2 vs 1/λ, showed quite similar
spectral bands for the analyte in the two analyzed solutions,
sample and standard (Figs. 2 and 3).
Brieﬂy, the negative bands of the second order derivative with
minimum at the same maximum on the zero-order band were quite
similar, sample and standard, coming from the two additional
positive satellite bands, the ﬁrst at 1174 cm1 and the second at
1158 cm1. This behavior was also observed for the other possible
analytical band whose maximum was found at 1335 cm1. Both
signal to noise ratio and baseline shift corrections were the
preponderant factors for discriminating between the two last
bands. In this sense, the band at 1165 cm1 provided the best
precision, sensitivity, and quantitative features.
3.3. Selection of the analytical measurement criterion
Various measurement criteria were evaluated using the second-
order derivative of the spectral band in the selected range
(Fig. 3B). Taking into account the main features of a linear
regression curve, we decided to select the area under the main
second-order band denoted as DZL (1170–1158 cm
1) in Table 1.
3.4. Effect of FTIR instrument conditions
A monoparametric study was performed by monitoring the
selected analytical signal for each variable by triplicate. As a
whole, a nominal resolution of 4 cm1, selected from 2 cm1 to
32 cm1 range, by accumulating 10 scans, selected from 1 scan to
50 scans, was chosen mainly as a compromise between precision
of o1.0% RSD and spectral acquisition time o60 s. On the other
hand, as a compromise with respect to sensitivity, precision, and
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was 9 points, selected from a 5 points to 37 points range, with a
related precision of 0.27% RSD, n¼3.1250 1220 1190 1160 1130 1100
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Figure 3 The zeroth (A) and second (B) derivative spectra of FUR
standard and FUR sample. Second order derivative of FUR as a
function of the concentration (C).
Table 1 Analytical ﬁgures obtained for FUR determination by FTIR
Band parameters (cm1)a Linear reg
Criterion Baseline mode Peak location Y¼aþb [X
a ( 105
Peak area DSL 1165 15.4
DSZ 1165 15.6
DZL 1165 10.6
DZ 1165 6.0
Peak height DS 1174 1.61
DB 1165 0.41
DL 1158 2.63
DZ 1165 2.11
aFig. 3B illustrates the different possibilities to obtain the intensity of the d
the short wavenumber peak satellite, and DB and DZ are the peak tangent b
bY¼2nd derivative signal; X¼FUR concentration ranging from 2.0 mg/m
cLOQ, limit of quantiﬁcation in mg/mL calculated as 10σ/slope; RSD
r¼correlation coefﬁcient.3.5. FTIR-DS system analytical ﬁgures of merit
3.5.1. Linearity
Data from the simple regression line described in Table 2
demonstrated acceptable FUR linearity over 20%–200% range of
the target concentration (10 mg/mL) with a quantiﬁcation limit of
1.0 mg/mL. The Y-intercept was negative but not signiﬁcantly
different from zero, P¼0.05. Furthermore, the y-intercept varia-
bility resulted less than 1% of the response obtained at the target
level which is usually an acceptable criterion40. The statistical
signiﬁcance of the regression line (r2¼0.9998) also revealed that
the slope is not zero, Po0.05, which in turn, suggested that
changes in the concentration variable are highly associated with
changes in the response variable (Table 2).
3.5.2. Precision
As can be seen in Table 2, data for instrument precision and
repeatability met the requirements for a method to be precise37.
3.5.3. Selectivity and speciﬁcity
The ﬁngerprint region is often the most complex and confusing
region to interpret. However, its utility is that many bands provide
a molecule pattern. Fortunately, FUR has an inorganic group,
S¼O, which absorbs in the IR ﬁngerprint region giving intense
vibrational bands, fewer in number and broader than those
observed for organic materials. These features generate a char-
acteristic IR spectrum. By appropriately selecting one of these
large bands, the method provided some grade of speciﬁcity. The
use of DS allowed demonstrating that the selected spectral region
for analytical purposes only belonged to the API (Fig. 2).
Nonspeciﬁc background interference and baseline shift were
automatically corrected by the conversion of the zero-order
derivative spectrum into the second-order derivative spectrum,
thus improving accuracy of quantiﬁcation.
The standard addition technique did not evidence spectral
interference due to concomitant absorbing species coming from
excipients. It is important to remember that the analyte is extracted
from the excipient using an organic solvent, where FUR is very
soluble. This cannot be said for the known common excipients-DS using different measurement modes.
ressionb Analytical parametersc
] r LOQ RSD
) b ( 103)
2.52 0.9996 2.00 0.50
2.01 0.9995 2.12 0.72
1.68 0.9999 1.03 0.32
1.42 0.9999 1.14 0.60
0.105 0.9998 1.46 1.38
0.347 0.9998 1.44 1.45
0.067 0.9997 1.56 1.55
0.254 0.9999 1.05 1.90
erivative spectral band; DL is the long wavenumber peak satellite, DS is
aseline and the peak-derivative zero, respectively.
L to 20.0 mg/mL (n¼10).
, relative standard deviation established at the target concentration;
Table 2 Analytical performance characteristics and system suitability of the proposed FTIR-DS method for determining FUR.
Parameter Result Observation
Dynamic linear range (mg/mL) 1.0–40.0 20–40 mg (Tab)
Working linear range (mg/mL) 2.0–20.0 –
Detector linearity (r2) 0.9998 Criterion: 40.9990
External linear regression Y¼1.1 105þ1.68 103 [X] Y¼D2peak area;
X¼concentration
SD of the response 0.00017 σ
Limit of quantiﬁcation (mg/mL) 1.03 (10σ)/slope
Correlation coefﬁcient 0.99988 Criterion: Z0.999
Statistical signiﬁcance of Y-intercept 0.90o2.36 mα¼0;
(Po0.05) tExpotTab; tn2
Statistical signiﬁcance of slope 17542.36 mβ¼0;
(Po0.05) tExpotTab; tn2
Instrument precision data from 10 replicate determinations 0.23% Acceptance criteria: r1.0%
(RSD)
Instrument precision data from 6 replicate determinations 0.31% Acceptance criteria: r2.0%
(RSD)(pharmaceutical sample)
Intra-assay precision by analyzing aliquots of a homogeneous sample,
independently prepared
0.45% for 8 mg/mL (n¼3) Acceptance criteria: r2.0%
(RSD)0.30% for 10 mg/mL (n¼3)
0.38% for 12 mg/mL (n¼3)
Intermediate precision: Acceptance criteria: 2.0–
5.0% (RSD)Operator 1, day 1 and day 2 0.83%
Operator 2, day 1 and day 2 1.6%
Operators, day 1 1.3%
Operators, day 2 1.2%
Analytical frequency (sample/h) 25 Manual sampling
Stability of analytical solutions (coefﬁcient of variation) 1.2% (n¼13) Cell removed after each
measurementTest period: 10–120 min.
Time extraction during sonication depending on FUR concentration in
sample to be prepared
o10 min 1 mg/mL
o15 min 10 mg/mL
o70 min 40 mg/mL
Sample carry over by ﬁlling the cell with a high standard concentration 0.16% Acceptance criteria: o2.0%
(RSD)(followed by a blank solvent
injection)
Standard deviation, SD. Relative standard deviation, RSD. Symbol “σ” represents SD(Y/X). Tablets, Tab. Second order derivative, D
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Figure 4 Representative FUR spectra in various commercial brands
and a FUR standard as reference. FUR standard, 8 mg/mL (spectrum
line 1), generic drug 1 (spectrum line 2), innovator drug (spectrum line
3), brand drug 1 (spectrum line 4), and generic drug 2 (spectrum
line 5). Nominal concentration of pharmaceuticals represents
10 mg/mL FUR.
Máximo Gallignani et al.380such as maize starch, talc, magnesium stearate, sodium starch
glycollate, and colloidal silicon dioxide, except for lactose, which
is very soluble in DMF2. Preliminary studies showed a lactose
transmission FTIR spectrum with absorption intensity values in the
1150–950 cm1 region, where solvent absorption saturation was
observed. The proximity of lactose absorption, characteristic IR
absorption of carbohydrate moieties, to FUR absorption only
caused displacement of the baseline (1158–1000 cm–1). Depending
on the pharmaceutical brand type, displacement was caused in one
more than the other (Fig. 2). This spectral interference was
corrected later on using second order DS.
Furthermore, as can be seen in Figs. 3 and 4, supplementary
studies demonstrated the viability of the intended objective of the
analytical procedure. The visual spectral evaluation showed similar
band shapes for all the commercial samples. Also, they were quite
similar to the standards. Certainly, at the level of the satellite bands
of the second derivative spectra, some spectral differences were
observed from sample to sample. Nevertheless, they were attrib-
uted to small variations in concentration (Fig. 3C) more than any
spectral interference from the excipients (Fig. 4).3.5.4. System suitability
Generalizing, Table 2 shows the analytical performance char-
acteristics of the FTIR-DS method for determining FUR. In thisparticular case, the table also shows some required analysis factors
used in order to guarantee system suitability, such as stability of
the sample solutions and percentage of extraction by sonication.
This last procedure, using DMF, is ofﬁcial in most compendium
pharmacopoeias. Although, in a lengthy procedure, several samples
can be extracted simultaneously, even during the pre-conditioning
FTIR derivative spectroscopy for estimation of furosemide in pharmaceutical dosage form 381of the analytical equipment. Variation coefﬁcients within an
acceptable range demonstrated that factors, which could affect
robustness of the method, had a negligible effect on the analytical
response (Table 2). Other parameters were determined via robust-
ness (Section 3.5.5).3.5.5. Robustness
In principle, the proposed method could be considered as very
simple. Consequently, it involved few parameters that could affect
the method performance. FTIR analytical procedures are usually
protected from changes in humidity and temperature. Therefore,
they were kept controlled throughout the methodological devel-
opment. The sample was introduced via ﬁlling ports. In this
regard, signal response variation due to cuvette manipulation was
kept to a minimum by prolonging sample application on the
entrance port. That is, the sample solution was passed through the
cell interior for at least 30 s at 0.5 mL/min. Additionally, when the
cell was ﬁlled with a high standard concentration, followed by a
blank solvent injection, the variation coefﬁcient due to sample
carry-over was very low (Table 2). Parameters such as pH and
composition of the dissolvent were not involved in the method
development. Possible DMF water content was corrected by the
background and the selected mode of quantiﬁcation, i.e. by DS. In
conclusion, the analytical conditions can be adequately controlled
and small changes in method parameters will show negligible
effects on the analytical response.Table 3 Results of assessment of the linearity of the FTIR-DS syst
technique.
Curve type Linear regression: Y¼aþb
a7SD; ( 103)
External (Reference standard) 0.1170.11
Standard addition 1 (Innovator) 3.7870.14
Standard addition 2 (Generic) 3.9870.20
aCalibration, where Y¼peak area of the 2nd derivative signal; X¼FUR
coefﬁcient.
Table 4 Recovery of FUR from pharmaceutical samples with know
Type of brand Sample No. Concentration of FUR (mg/mL); n¼
Nominal Added
Innovator 1 2.21 4.0
2 8.0
3 10.0
4 12.0
5 18.0
Generic 1 2.39 4.0
2 8.0
3 10.0
4 12.0
5 18.0
aThe acceptable recovery is for the analysis of 1% (w/v) active ingredien
recovery will be (10072)% at each concentration over the range of 80%–13.5.6. Accuracy
Samples spiked with known quantities of the API were analyzed. The
standard addition calibration test of signiﬁcance for the innovator
product showed that the estimated y-intercept was different from zero
(Po0.05) using H0: mα¼0 (tExpotTab), the result being 2742.36.
A similar result was observed for the y-intercept standard addition
calibration for one of the representative generic products, 2042.36.
On the other hand, the standard addition slope belonging to the
innovator product was within the conﬁdence limits of the slope of
reference (1.68 10372.3 104) at the 0.05 level of signiﬁcance.
An identical result was observed for the standard addition slope of one
representative generic product (Table 3). The relative percentage
deviation between the reference slope (b) belonging to the external
calibration and the other two slopes, (b1) and (b2), was less than 1.2%.
This indicated that the sensitivity of the analyte was only slightly
affected by the presence of any interference coming from the inactive
substance formulated alongside the API.
Furthermore, assay percentage recovery of known added amounts
of API in the pharmaceutical sample was also explored (Table 4).
The mean recovery for the proposed assay method resulted within
(10073)% over the 80%–120% range of the target concentration for
the innovator and generic pharmaceutical products. Considering that
the expected recovery depends on the sample matrix, the sample
processing procedure and the analyte concentration, the accuracy of
the proposed method can be considered suitable for determining
FUR content in solid dosage pharmaceutical products.
Additionally, an ofﬁcial reference assay method was used to
estimate the accuracy of the proposed method. In the global F testem for the assay method of FUR employing the addition standard
[X]a
b7SD; ( 103) r SD(y/x)
1.6870.0096 0.99988 0.00017
1.7070.014 0.99976 0.00024
1.7070.021 0.99949 0.00034
concentration in mg/mL (n¼9); SD, standard deviation; r¼correlation
n concentration using the proposed FTIR-DS method.
3 Recovery (%) Recovery (%)
Found Mean Acceptable a
6.40 104.8 102.371.9 97–103
10.41 102.6
12.59 102.8
14.16 99.6
20.50 101.6
6.58 104.8 101.272.4 97–103
10.50 101.4
12.26 98.8
14.28 99.1
20.72 101.9
t37. The accuracy criteria for an assay method (FDA) is that the mean
20% of the target concentration40.
Table 5 Analytical application of the proposed FTIR-DS method for determining FUR in solid dosage pharmaceutical products.
Type of branded drug Concentration (mg/Tab)7SD; n¼6
Labeled Found Reference HPLC methoda
FTIR-DS method Found Accepted range
Innovator 1 20 20.970.30 19.070.10 18–22
Generic 1 40 39.970.31 40.270.56 36–44
Brand 1 40 41.370.10 41.670.60 36–44
Brand 2 40 40.870.20 39.6970.77 36–44
Innovator 2 40 41.970.70 – 36–44
Generic 2 40 44.970.31 – 36–44
Generic 3 40 39.670.20 – 36–44
Bulkb 99.05 99.070.26b – 98–101
aUSP17. The symbol (–) means that it was not analyzed by the method of reference.
bIt represents dried substance or raw material powder. USP acceptance range in % w/w17.
Máximo Gallignani et al.382from the ANOVA table, we obtained a F-ratio equal to 0.036 and a
P value greater than 0.05. Therefore, we concluded that there was
insufﬁcient evidence to assume any bias between the methods at
the 95% conﬁdence level (Table 5).4. Conclusions
The developed method for determining FUR based on the
application of transmission FTIR in the liquid phase fulﬁlled most
validation requirements in a range of concentrations suitable for
quality control of both incoming raw materials and solid dosage
forms (Tables 2 and 5). Therefore, this is a pharmaceutical
industry quality control method that could be considered inter-
changeable with other pharmacopoeial methods. As referenced in
practically all compendium pharmacopoeias, the major use of
FTIR in the transmission mode is for the identiﬁcation of API in
raw materials and ﬁnished products. Regardless of the many
advantages described in the last two decades28, FTIR equipment in
the pharmaceutical ﬁeld for qualitative issues is widely available
but still undervalued for quantitative purposes. We believe that
FTIR instruments in conjunction with DS are ideal tools for
pharmaceutical quality control. By comparison with compendial
and non-compendial analytical methods, the proposed FTIR-DS
method reduces solvent consumption and eliminates the use of
reagents. Additionally, the proposed FTIR-DS method allows off-
site re-analysis of spectra for other chemicals not originally
targeted. Finally, by selecting different measurement spectral
bands, this study opens up the possibility of applying the proposed
FTIR-DS method to quantify FUR when combined with other API
in the same dosage form.
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